Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 9/20 | 0.44 |
| ▸ | CA2 | P00918 | 9/20 | 0.44 |
| ▸ | CA12 | O43570 | 7/20 | 0.44 |
| ▸ | CA9 | Q16790 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455954 | 0.86 | TDP1 (0.57) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL28300057 | 0.83 | TDP1 (0.63) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL1897482 | 0.83 | CA1 (0.47) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL674127 | 0.82 | TDP1 (0.61) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL13055393 | 0.82 | TDP1 (0.58) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL19179935 | 0.82 | TDP1 (0.57) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL23728653 | 0.81 | TDP1 (0.59) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL30537805 | 0.81 | TDP1 (0.59) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL31395855 | 0.81 | TDP1 (0.59) | TDP1CA1CA2CA12CA9 | |
| SCHEMBL18365027 | 0.81 | TDP1 (0.59) | TDP1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135347-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | PROLYNX LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20200054756-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | PROLYNX LLC (US) | 2020-02-20 | — | — | US | disclosed |
| US-10398779-B2 | Hydrogels with biodegradable crosslinking | PROLYNX LLC (US) | 2019-09-03 | — | — | US | disclosed |
| US-20170312368-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | PROLYNX LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-9649385-B2 | Hydrogels with biodegradable crosslinking | PROLYNX LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20140288190-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | PROLYNX LLC (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398779-B2 | Hydrogels with biodegradable crosslinking | IDUA, APEH, GUSB | TDP1 326/4885CA1 1061/4885CA2 1051/4885 |
| US-20140288190-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | HAAO, MMP1, SI | TDP1 446/4885CA1 618/4885CA2 695/4885 |
| US-20230135347-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | IDUA, APEH, GUSB | TDP1 326/4885CA1 1061/4885CA2 1051/4885 |
| US-20170312368-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | IDUA, APEH, GUSB | TDP1 326/4885CA1 1061/4885CA2 1051/4885 |
| US-20200054756-A1 | HYDROGELS WITH BIODEGRADABLE CROSSLINKING | IDUA, APEH, GUSB | TDP1 326/4885CA1 1061/4885CA2 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.